Select Your Region
Americas
Europa
Afrika
Weltweit
Anwendungsbeobachtung zur Beurteilung von Rituximab und der Verwendung des Rituximab-Therapiepasses bei Teilnehmenden, die eine Rituximab-Infusion für eine nicht-onkologische Indikation an Infusionszentren in Europa erhalten
Observational Study Evaluating Rituximab Use and Use of the Patient Alert Card in Participants Receiving Rituximab Infusion for a Non-Oncology Indication at Infusion Centers in Europe
- Krebs
Bitte beachten Sie, dass der Rekrutierungsstatus der Studie an Ihrem Standort vom Gesamtstatus der Studie abweichen kann, da einige Studienzentren früher rekrutieren als andere.
Status der Studie:
Abgeschlossen
Diese Studie läuft in
Städte
- Dresden
- Frankfurt am Main
- Freiburg im Breisgau
- Gommern
- Halle (Saale)
- Heidelberg
- Lübeck
- Mainz
- Ratingen
Studien-ID:
NCT02654379 BA28478
Studienzusammenfassung
This study is to characterize the indications for which rituximab is being used and to evaluate the use of the Patient Alert Card (PAC) in participants receiving the medication for non-oncology conditions at infusion centers. The study involves the retrospective chart review of rituximab users' medical records in non-oncology indications as well as a survey to collect information on participant characteristics, and will include questions about participant knowledge on the risk of infections, participant receipt and review of the PAC, and any actions the participant has taken as a result of receiving the PAC.
Hoffmann-La Roche
Sponsor
NCT02654379,BA28478
Studien-ID
Rituximab
Treatments
Off-Label Use
Condition
Official Title
MabThera Drug Utilisation Study and Patient Alert Card Evaluation in Non-Oncology Patients in Europe: An Infusion Centre-Based Approach
Einschlusskriterien
All
Gender
≥ 18 Years
Age
No
Healthy Volunteers
Inclusion Criteria
- Participant is in the center to receive an infusion for rituximab for a non-oncology indication during the study period
- Aged 18 years or older
Exclusion Criteria
- Has previously already completed the rituximab survey
- Has participated in the past 12 months in a clinical trial in which rituximab was one of the treatments being evaluated.
Um die aktuellste Version dieser Seite aufzurufen gehen Sie bitte auf www.Klinische-studien-für-patienten.de
